Navigation Links
Cellectis bioresearch First to Launch Revolutionary Custom TAL Nuclease Service
Date:1/25/2011

PARIS, Jan. 25, 2011 /PRNewswire/ -- Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis (Alternext: ALCLS), has today announced that it will launch gene specific TAL(1) nucleases on February 28, 2011.

Taking advantage of an exclusive license agreement with the University of Minnesota, Cellectis has rapidly integrated TAL effector nucleases into its DNA nuclease production platform. TAL effector nucleases are sequence specific DNA scissors that can be custom engineered to target and modify any gene of interest, in any species. Cellectis is able to produce TAL nucleases in around one week, providing scientists with rapid access to custom-made products.

"This technology has a huge potential and could revolutionize the genome customization world. Being the first to launch TAL nuclease services puts us in an attractive position to gain significant share of the multimillion dollar market for custom DNA nucleases," explained Marc Le Bozec, CEO of Cellectis bioresearch.

"We add yet another asset to our portfolio of important genome customization tools, and invite you to visit our website on February 28, for the official launch of our custom TAL nuclease offer," added Luc Selig, VP Sales and Marketing of Cellectis bioresearch.

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization.  These tools, based on sequence specific endonucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene function studies. The genome customization products and services can be purchased online from www.cellectis-bioresearch.com.

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

More information at www.cellectis.com  

Follow Cellectis on Twitter at www.twitter.com/cellectis.  

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

(1) TAL: transcription activator-like


'/>"/>
SOURCE Cellectis bioresearch
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
2. Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
3. Cellectis to Present at the FASEB Summer Research Conference on Genome Engineering
4. Cellectis bioresearch Establishes The Genome Customization Award (TGCA)
5. Taconics Litigation Contesting License Termination By Cellectis Is Dismissed
6. Cellectis Unveils Its New Corporate Website
7. Cellectis Bioresearch Announces Availability of Research Kits Through New Online E-Store
8. Cellectis Plant Sciences Licenses Plant Transformation Technology From Midwest Oilseeds
9. Cellectis and the Center for iPS Cells Research and Application Enter Collaboration
10. Cellectis Plant Sciences Licenses Plant Transformation Technology for Corn and Rice
11. Cellectis bioresearch Signs Non-Exclusive License With Evrogen for Access to Fluorescent Proteins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Parallel 6 , the leading software as a ... Reach Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine ... team. , Using the CONSULT module, patients and physicians can schedule a face to ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former ... of the University of North Carolina Kenan-Flagler Business School effective June ... UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes and ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
Breaking Biology News(10 mins):